This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Liandong Ji
Xiangya Hospital Central South University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Autoimmune pancreatitis (AIP) is a rare disease, have a dramatic response to steroid therapy, but the relapse rates(RRs) is very high, and the side effects of steroid therapy are inevitable. The aim of this study is to focus on the management of relapse and side effects.
Methods: A single-centre, retrospective, cohort study of the type Ⅰ AIP patients admitted to Xiangya Hospital Central South University from September 2008 to September 2019 conducted. Collection and retrospectively analyzed the clinicopathologic data and outcomes of these patients.
Results: 82 patients were included, 73.2% were histologically confirmed. 78.0% treated by medications: 62.5% prednisolone, 37.5% prednisolone plus cyclophosphamide. The RRs of the two group have no significant difference (35.0% vs 29.2%, P = 0.630). Increasing the dosage of prednisolone, the effective rate of the prednisolone treatment and prednisolone plus cyclophosphamide treatment relapsed patients were 78.57% and 71.43%, respectively. The side effects were DM in 12.5%; central obesity in 15.6%; hyperlipidemia in 18.8%; gastric ulcer in 6.3%; osteoporosis in 9.4%; bone fracture in 1.6%. For those side effects patients performed low dose prednisolone and expectant treatment have a ideal results.
Conclusions: Increasing the dose of prednisolone can effectively treat relapsed patients. Low dose steroid and expectant treatment should be performed when side effects arised.
Keywords
Autoimmune Pancreatitis (AIP), Immunoglobulin G4 (IgG4), Other Organ Involvement (OOI), Relapse Rates (RRs), side effects
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 12 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Liandong Ji
Xiangya Hospital Central South University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 12 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Autoimmune pancreatitis (AIP) is a rare disease, have a dramatic response to steroid therapy, but the relapse rates(RRs) is very high, and the side effects of steroid therapy are inevitable. The aim of this study is to focus on the management of relapse and side effects.
Methods: A single-centre, retrospective, cohort study of the type Ⅰ AIP patients admitted to Xiangya Hospital Central South University from September 2008 to September 2019 conducted. Collection and retrospectively analyzed the clinicopathologic data and outcomes of these patients.
Results: 82 patients were included, 73.2% were histologically confirmed. 78.0% treated by medications: 62.5% prednisolone, 37.5% prednisolone plus cyclophosphamide. The RRs of the two group have no significant difference (35.0% vs 29.2%, P = 0.630). Increasing the dosage of prednisolone, the effective rate of the prednisolone treatment and prednisolone plus cyclophosphamide treatment relapsed patients were 78.57% and 71.43%, respectively. The side effects were DM in 12.5%; central obesity in 15.6%; hyperlipidemia in 18.8%; gastric ulcer in 6.3%; osteoporosis in 9.4%; bone fracture in 1.6%. For those side effects patients performed low dose prednisolone and expectant treatment have a ideal results.
Conclusions: Increasing the dose of prednisolone can effectively treat relapsed patients. Low dose steroid and expectant treatment should be performed when side effects arised.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...